BioCentury
ARTICLE | Company News

Cytyc to acquire Adeza

February 13, 2007 1:14 AM UTC

CYTC agreed to acquire women's health company ADZA for $24 per share, or $452 million. The price is a 55% premium to ADZA's close of $15.53 on Friday. The deal will give CYTC, which markets surgical and diagnostic products focused on women's health and cancer, FullTerm, a marketed fetal fibronectin test that identifies women at risk of preterm birth; and Gestiva to prevent preterm birth in women with a history of preterm delivery. ADZA received an FDA approvable letter for Gestiva in October in which the agency requested an additional animal study among other conditions. Gestiva is a long-acting form of a naturally occurring progesterone, 17 alpha-hydroxyprogesterone caproate (17P). ...